In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr.

Nura Bio, Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, announced today the ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s ...

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for ...

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...

Celgene's European leader Tuomo Pätsi talks to pharmaphorum about the firm's remarkable growth, which is set to continue thanks to myeloma blockbuster Revlimid and new psoriasis and psoriatic ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...